This article is sponsored by Johnson & Johnson. | Explore a quadruplet treatment regimen now approved for newly diagnosed multiple myeloma patients who are transplant ineligible.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
BeOne wins FDA approval in lymphoma race
Integrated CDO capabilities reduce early development complexity
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
FDA revisits a rare cancer treatment it rejected a few months ago
Eli Lilly delivers $50M boost to UNICEF’s pediatric health push
Targeted Protein Degradation and Novel Modalities: Getting on the Frontline
Five years after disaster, a rare disease community gets new chance at treatment
Updated: BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
FDA floats possible approach to repurpose approved drugs under new uses
Eisai's slow push toward blockbuster Leqembi sales gains steam with $900M forecast
